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Abstract
Heme oxygenase 1 (HO-1) is an essential enzyme induced by heme and multiple stimuli associated with critical illness. In
humans, polymorphisms in the HMOX1 gene promoter may influence the magnitude of HO-1 expression. In many diseases
including murine malaria, HO-1 induction produces protective anti-inflammatory effects, but observations from patients
suggest these may be limited to a narrow range of HO-1 induction, prompting us to investigate the role of HO-1 in malaria
infection. In 307 Gambian children with either severe or uncomplicated P. falciparum malaria, we characterized the
associations of HMOX1 promoter polymorphisms, HMOX1 mRNA inducibility, HO-1 protein levels in leucocytes (flow
cytometry), and plasma (ELISA) with disease severity. The (GT)n repeat polymorphism in the HMOX1 promoter was
associated with HMOX1 mRNA expression in white blood cells in vitro, and with severe disease and death, while high HO-1
levels were associated with severe disease. Neutrophils were the main HO-1-expressing cells in peripheral blood, and
HMOX1 mRNA expression was upregulated by heme-moieties of lysed erythrocytes. We provide mechanistic evidence that
induction of HMOX1 expression in neutrophils potentiates the respiratory burst, and propose this may be part of the causal
pathway explaining the association between short (GT)n repeats and increased disease severity in malaria and other critical
illnesses. Our findings suggest a genetic predisposition to higher levels of HO-1 is associated with severe illness, and
enhances the neutrophil burst leading to oxidative damage of endothelial cells. These add important information to the
discussion about possible therapeutic manipulation of HO-1 in critically ill patients.
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Introduction
Heme oxygenase (HO) is the rate limiting enzyme that
catabolizes free heme into carbon monoxide (CO), ferrous iron,
and biliverdin/bilirubin [1]. To date, two functional isoforms
(HO-1, HO-2) have been described. While HO-2 is constitutively
produced by most cells, HO-1 protein is induced by its substrate
heme and a broad array of acute stress stimuli, many of which are
associated with critical illnesses [2]. HO-1 induction produces
cytoprotective and anti-inflammatory effects by reducing intracel-
lular heme availability, through generation of CO and bilirubin,
through stimulation of ferritin synthesis [3], and possibly, by
heme-independent mechanisms of transcriptional regulation [4].
HO-1 is an essential enzyme in humans and mice; deficiency in
humans is deleterious, predominantly affecting endothelial cells
and the reticuloendothelial system, and results in a greatly reduced
life expectancy [5]. However, much of what is known about HO-1
function is derived from experiments in animal models or in in vitro
experiments. The impact of HMOX1 over- or under-expression,
silencing or knockout and the concomitant changes in protein
levels in a physiological or homeostatic context [6] or in humans
[7] is less clear.
The blood stage of malaria infection is characterized by
hemolysis and consequent release of hemoglobin and its heme
moiety [8]. Elegant mechanistic studies in mice have shown that
free heme has a profound pro-inflammatory and cytotoxic effect in
malaria, increasing susceptibility to experimental cerebral malaria
(ECM), and hepatic failure. These adverse events can be
prevented by HO-1 induction or administration of CO that can
reduce the levels of free heme [9,10]. Marked differences amongst
mouse strains in the kinetics of HO-1 in response to P. berghei
ANKA infection appeared to determine susceptibility to ECM,
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in this model. However, higher HO-1 levels in the murine liver
appeared to allow the development of liver stage parasites by
reducing the host inflammatory response, indicating that optimal
regulation of HO-1 must balance control of pathogen replication
with protection from inflammatory damage during infection [11].
As expected, evidence of increased expression and activity of
HO-1 has been observed in human malaria [12,13,14,15], but its
functional relevance has been far more difficult to establish. Other
than inbred mice, the amount of HO-1 produced in response to a
defined stimulus in humans may be influenced by a (GT)n repeat
length polymorphism in the promoter region of the HMOX1 gene
[16]. In various chronic inflammatory conditions and other
diseases, long HMOX1 (GT)n repeats, associated with lower HO-
1 protein have been identified as disease risk factors [17]. This has
led to the hypothesis that the ability to mount a strong HO-1
response is beneficial for people living in malaria endemic areas,
and that the disease may have applied selective pressure for shorter
(GT)n repeats [17].
The potential role of HO-1 and CO has also been recognized in
other critical illnesses [18], and in a murine model free heme
clearly contributed to the pathogenesis of severe sepsis [19]. If the
protective effect of CO or other products of the enzymatic reaction
catalyzed by HO-1 can be established in man, this could provide
novel avenues for treatment using therapeutic CO inhalation, or
systemic administration of CO releasing molecules (CORM),
capable of releasing CO in a controlled fashion [20]. HO-1 has
thus moved to ‘‘center stage’’ for a variety of infectious diseases,
not just for malaria [20,21]. A recent report on critically ill patients
measuring CO bound hemoglobin (COHb) levels of which 85%
can be ascribed to HO-1 mediated heme metabolism [22]
indicates that both excessively low or high levels of COHb appear
to be associated with death [23]. This indicates that the protective
effects of HO-1 are limited to a narrow range of HO-1
concentrations [18].
While HO-1 uses the highly cytotoxic heme as a substrate, one
of the products of the enzymatic reaction, ferrous iron, is released
into the endoplasmic reticulum (ER). In this form, iron is redox
active and can catalyze the formation of organic and inorganic
reactive oxygen species (ROS) [24]. HO-1 thus has both anti-
oxidant and oxidant properties. In malaria its induction may be
particularly enhanced by a pronounced intravascular hemolysis
liberating considerable amounts of heme [25] that require
degradation by HO-1 in endothelial cells, resulting in an increase
of ferrous iron. Indeed, in vitro studies indicate that the equimolar
production of anti-oxidant bilirubin and ferrous iron by HO-1
results in an overall pro-oxidant effect [26], and that high HO-1
levels can lead to tissue damage [27]. In light of this, it has been
hypothesized with regard to the effect of the (GT)n repeat length
polymorphism in the HMOX1 gene promoter that – in contrast to
what has been observed for chronic inflammatory conditions -
short repeat array alleles may cause susceptibility to severe malaria
in humans [28]. Consistent with this, short alleles were found to be
associated with risk of cerebral malaria in Myanmar [29], and
Angola [30].
The functional duality is problematic with respect to developing
adjuvant therapies for severe malaria based on induction of HO-1
or administration of CO, and highlights the need to understand
better the regulation and function of HO-1 in humans in relation
to both promoter polymorphisms and malaria.
In the present study we characterized in detail the genetic and
functional associations between HMOX1 promoter polymor-
phisms, HO- 1 inducibility, HMOX1 expression and severity of
malaria in Gambian children exposed to seasonal malaria. We
show that short (GT)n repeat alleles in the HMOX1 gene are
associated with higher HMOX1 expression in white blood cells of
this population, and that short repeat alleles are strongly associated
with severe disease and death, whilst high HMOX1 mRNA and
HO-1 protein levels are associated with severe disease. We
establish that neutrophils are the main HO-1 expressing cell type
in peripheral blood ex vivo, and demonstrate in vitro that HMOX1
mRNA expression in purified neutrophils can be upregulated
further by lysed erythrocytes, or hemin. We provide mechanistic
evidence that hemin-mediated HMOX1 expression potentiates the
neutrophil respiratory burst, and propose that this may be part of a
causal pathway driving the association between short (GT)n
repeats and increased disease severity.
Materials and Methods
Ethics statement
The study was reviewed and approved by the Gambian
Government/MRC Joint Ethics Committee and the Ethics
Committee of the London School of Hygiene & Tropical
Medicine (London, UK). Between September 2007 and January
2010, after written informed consent was obtained from the
parents or guardians, a total of 153 severe and 154 uncomplicated
malaria cases were enrolled. (see Table S1 in Text S1 for detailed
information).
Subject recruitment, study design and study procedures
Subjects enrolled in this study were recruited from an ongoing
health centre based study comparing children with uncomplicated
and severe malaria disease resident in a restricted peri-urban area
of the Gambia described in more detail previously [31].
Uncomplicated malaria (UM) was defined as an episode of fever
(temperature .37.5uC) within the last 48 hours with more than
5000 parasites/ml detected by slide microscopy. Severe malaria
(SM) was defined using modified WHO criteria [32]: severe
anaemia (SA), defined as Hb,6 g/dl; severe respiratory distress
(SRD) defined as serum lactate .7 mmol/L; cerebral malaria
Author Summary
HO-1 is an important anti-inflammatory enzyme induced
by several stimuli associated with critical illness. In humans,
the amount of HO-1 produced is influenced by a genetic
polymorphism in the gene promoter region. Using
Plasmodium falciparum malaria that can cause a sepsis-
like syndrome as an example, we characterize the
associations between the (GT)n polymorphism, HO-1
protein levels and HMOX1-mRNA expression with severity
of malaria in 307 Gambian children. Our results support
the functionality of this polymorphism, demonstrate that
P. falciparum infections increase HO-1 levels, and indicate
that a genetic predisposition to strongly upregulate HO-1
is associated with severe forms of malaria and increased
risk of dying. We identify neutrophils as the main HO-1-
producing blood cells, and provide evidence that hemin-
mediated induction of HMOX1 in neutrophils in vitro
enhances the oxidative burst. In this way sequestered
neutrophils may contribute to oxidative damage of
endothelial cells, which may be part of a causal pathway
explaining the association between short (GT)n repeats
and increased disease severity. Our findings imply that the
beneficial effects of HO-1 may be limited to a narrow
window of concentrations, which should be born in mind
when considering the therapeutic potential of manipulat-
ing HO-1 induction in critically ill patients.
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hypoglycaemia or hypovolaemia, with the coma lasting at least for
2 hours; severe prostration (SP) defined as inability to sit
unsupported (children.6 months) or inability to suck (children#6
month). The term ‘‘disease severity’’ refers to comparisons
between UM and SM, and, where indicated, to a comparison
across disease entities grouped according to increasing severity. To
avoid the confounding effects of other pathogens in children with
concomitant systemic bacterial infections, children with clinical
evidence of infections other than malaria were not enrolled into
the study. For some experiments, healthy children (HC, n=6) of
the same age were enrolled as controls. On admission (D0, also
referred to as ‘‘acute disease’’) and after 4 weeks (D2863 days, also
referred to as ‘‘convalescence’’) one ml of blood was collected in
RNA stabilizing agent (PAXgene Blood RNA system, Pre-
AnalytiX) and a maximum of 4 mls of blood (mean: 3.2 mls CI
95%: 3.1–3.3 mls) were collected into heparinized vacutainers
(BD). Four buccal swabs were performed using sterile mouth
brushes (Cytobrush plus, Henley’s Medical, UK) and stored in a
DNA-stabilizing buffer containing 10 mM Tris, 10 mM EDTA,
0.5% Sarkosyl for subsequent DNA extraction. All patients
received standard care according to the Gambian Government
Treatment Guidelines, provided by the health centre staff. The
children’s health was reviewed 7 days after admission. Healthy
adult volunteers were bled for the in vitro experiments after
informed consent was obtained.
P. falciparum parasites were identified by slide microscopy of 50
high power fields of a thick film. Full differential blood counts were
obtained on days 0 and 28 using a Medonic instrument (Clinical
Diagnostics Solutions, Inc).
Cell preparation
Blood samples were processed within 2 hours of collection. Flow
cytometry was performed on 300 ml of whole blood collected into
heparinized tubes. HO-1 induction assays were performed on
200 ml of whole blood collected on D28. From the remaining
sample, plasma was removed, stored at 280uC and replaced by an
equal volume of RPMI 1640 (Sigma-Aldrich). PBMC were isolated
after density centrifugation over a 1.077 Nycoprep (Nycomed,
Sweden) gradient (800 g, 30 min) and washed twice in RPM 1640.
PBMCs were used for other studies [31]. The remaining PBMC
deficient blood suspension underwent a further density centrifuga-
tion over Histopaque 1119 (Sigma Aldrich) to isolate granulocytes
that were used for Western blood analysis of HO-1 expression after
a microscopic purity check with Giemsa stain.
Flow cytometry
Whole blood was incubated for 35 min at 4u in the dark with
the following cocktail of surface antibodies: 5 ml each of PE anti-
CD16b, Per CP anti-CD14, PE-Cy7 anti-CD4, APC anti-CD19
(all Becton Dickinson), Pacific blue anti-CD3 and 4 ul of APC-AF
750 anti-HLA-DR (both Ebioscience), or a cocktail of manufac-
turer matched isotype controls. Thereafter, erythrocytes were
lysed using FACS lysing buffer (Becton Dickinson), and the
remaining cells were fixed and permeabilized (Cytofix/Perm
reagent; Becton Dickinson). After a blocking step with 5% of
mouse serum (4uC, 15 min) intracellular staining (4uC, 30 min) for
HO-1 was performed with 3.5 ml of FITC anti-HO-1 (Abcam).
Samples were acquired on a 3 laser/9 channel CyAn ADP
flowcytometer and analysed using FlowJo 7.25 (Tree Star Inc.).
RT-PCR
For quantitative reverse transcription-polymerase chain reaction
(qRT-PCR), total RNA was extracted from PAX tubes, collected
from study patients following the manufacturer’s instructions and
reverse transcribed into cDNA using TaqMan reagents for reverse
transcription (Applied Biosystems), according to the manufacturer’s
protocol. In addition, whole blood used for HO-1 induction assays
from samples obtained on day 28 were collected into Trizol LS
(Invitrogen) and the RNA precipitated by a chloroform/ethanol
step. Isolation of RNA from neutrophils or whole blood used in the
in vitroassayswas performed withtheRNeasyMinikit(Qiagen)after
collection and storage of the cells into RLT buffer. Gene expression
profile for IL-10 was measured previously on a subset of samples
from the clinical study and were used for correlation analysis [31].
HMOX1 gene expression was determined by qRT-PCR on a DNA
Engine Opticon (MJ Research) using the TaqMan Probe kit with
primers (all Metabion) as previously published [33]. 18S rRNA,
amplified using a commercially available kit (rRNA primers and
VIC labeled probe, Applied Biosystems), was assayed as a
housekeeping gene with a stable expression profile in this setting
regardless of disease severity or time point [31]. Data were analysed
using Opticon Monitor 3 analysis software (BioRad) and are
expressedastheratioofthetranscriptnumberof the gene ofinterest
over the endogenous control, 18S rRNA.
HO-1 ELISA
Levels of soluble HO-1 were determined in plasma (1:50
diluted) or cell culture supernatants (neat) by ELISA in duplicate
wells of Immunolon HX4 plates, using the HO-1 human
ImmunoSet Kit (Stressgen).
Histidine rich protein-2 (HRP-2) ELISA
A commercial HRP-2 ELISA kit (CELISA, Cellabs, Australia)
was used to quantify HRP-2 in plasma samples diluted 1:20, in
duplicate wells of Immunolon HX4 plates. Some samples were out
of range and were repeated at a 1:2 dilution if below the bottom of
the standard curve, or at a 1:100 dilution if above the top of the
standard curve.
Heme measurement
Free heme in plasma was quantified using a published method
[9]. Briefly, plasma was centrifuged at 1000 g for 5 min and the
supernatant passed through a Microcon YM-3 column (Millipore,
14,000 g for 100 min at RT) to remove proteins. Free heme from
protein depleted plasma and heme content in lysates of infected
and uninfected RBC as well as a solution of uninfected intact RBC
was quantified by a chromogenic assay (QuantiChrom Heme
Assay Kit, BioAssay Systems).
Western blot
Immunodetection of HO-1 protein in lysates of isolated
neutrophils was performed using a protocol adapted from [4].
Polyclonal rabbit anti-HO-1 antibodies obtained from StressGen
Biotechnologies Corp. (Victoria, BC, Canada) were used.
Polyclonal goat anti-actin (Santa Cruz) antiserum was used for
staining as loading controls. Briefly, 10 mg of cell lysate proteins
was separated by reducing sodium dodecyl sulphate polyacryl-
amide gel electrophoresis using precast Nupage gels and MOPs
buffer in the X-cell mini electrophoresis chamber (Life Technol-
ogies). Separated proteins were then transferred onto methanol
treated PVDF membranes using the X-cell mini blotting system.
Blotted membranes were rinsed in 16PBS and blocked overnight
at 4uC in blocking buffer containing 5% non-fat milk in 16PBS
and 0.1% Tween 20 (Sigma Aldrich). After the blotted membranes
were washed three times in PBS-Tween, they were incubated with
constant shaking for 2 h at RT with anti-HO-1, or anti-actin
HO-1 Associated with Severe Malaria
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washed with three changes of PBS-Tween and further probed with
horseradish peroxidase-conjugated donkey anti-goat or goat anti-
rabbit IgG (Santa Cruz) at a dilution of 1:10,000 for 2 hours at
room temperature with constant shaking. Following three washes
in PBS-Tween, membranes were rinsed in 16PBS and bound
antibodies were revealed by chemiluminescent detection per-
formed with the Amersham ECL detection kit according to the
manufacturer’s instructions.
Analysis of the HMOX1 promoter (GT)n repeat length
polymorphism
Material from mouth brushes was eluted into transport buffer
and incubated with Proteinase K, guanidine hydrochloride, and
ammonium acetate (Sigma Aldrich, UK, at final concentrations of
262 ml/ml, 1.57M and 0.59M, respectively), for 1 hr at 60uC. Ice
cold chloroform was added to each sample at a ratio of 1 to 1.9
followed by a 5 min centrifugation at 1000 g. The upper layer was
transferred onto 10 mls pure ethanol and kept at 220uC for
1 hour to precipitate the DNA. After 15 min centrifugation at
1200 g the pellet was resuspended in 70% ethanol, washed again
(1200 g, 5 min), resuspended in 100 ml 1X TE buffer (Sigma
Aldrich, UK), and stored at 220uC until processing.
The 59-flanking region of the HMOX1 gene containing a (GT)n
repeat was amplified by PCR using a fluorescein-conjugated sense
primer(HMOX1_microsat_(9/10)59-AGAGCCTGCAGCTTCT-
CAGA- 39) and an antisense primer HeOP-1/R HMOX-1mi (1/3)
59-ACAAAGTCTGGCCATAGGAC-39) previously described
[29,34]. Samples that did not amplify with these primers were
amplified using a second set of primers; HMOX-2micro-Fwd (2/3)
59 CTTTCTGGAACCTT CTGGGAC 39 designed according to
thepublished sequence [35]andthe aboveantisenseprimer.Thirty-
five cycles were performed under the following conditions; 96u for
1 minute,95u for30 seconds,60u for30 seconds, 72u for3 minutes.
The sizes of the microsatellites were determined by the use of a laser
based automated DNA sequencer; ABI genetic analyser 3130xl
(Applied Biosystems, Forster City, Calif, USA), with a cloned
fragment of 28 bp that was used as a size marker. Allele scoring was
performed using GeneMapper version 4.0 (Applied Biosystems,
Forster City, Calif, USA), by 2 investigators blinded to the disease
status of donors. For analysis purposes, alleles were subsequently
divided into ‘‘S’’ (for short ,27 repeats), ‘‘M’’ (for medium 27 to 32
repeats), and class ‘‘L’’ (for long .32 repeats), using an established
classification [33,34,36].
Erythrocyte polymorphisms
To determine the frequency of Glucose 6 Phosphate Dehydro-
genase (G6PD) deficiency, genomic DNA was genotyped for SNPs
A376G (rs1050829) (G6PD A), G202A (rs1050828) (G6PD A-),
and T968C (G6PD A-) [37] that are mutations causing reduced
enzyme activity [38]. In order to infer the frequency of individuals
with blood group O, rs8176719 was typed to identify the frame
shift deletion at this position that encodes the O allele [39].
Genotyping was performed on a Sequenom MassArray
platform [40]. For each reaction 20 ng of gDNA was used and
each genotype was replicated three times. Sickle cell status was
determined by metabisulfite test and the genotype was confirmed
by cellulose acetate electrophoresis [31].
In vitro induction of HO-1 in whole blood by heat or
hemin
From a subset of participants (12 SM, 20 UM), 200 ml of whole
blood collected at D28 were kept for 3 hours at 37uC, at 40uC
(water bath), or stimulated with hemin (10 mM, Sigma Aldrich) at
room temperature, to determine inducibility of HO-1 mRNA. An
additional 6 samples from healthy controls were processed
similarly. After the incubation, samples were diluted 1:1 in RNAse
free water, and transferred into Trizol LS reagent (Life
Technologies). RNA processing and HMOX-1 gene expression
was carried out as described under qRT-PCR.
Preparation of P. falciparum schizont antigen extract
P. falciparum parasites (3D7 clone) were cultured in vitro as
described [31], and were routinely shown to be mycoplasma free
by PCR (Bio Whittaker). Schizont-infected erythrocytes were
harvested from synchronized cultures by centrifugation through a
Percoll gradient (Sigma-Aldrich). P. falciparum schizont extracts
(PfSE) was prepared by three rapid freeze-thaw cycles between
liquid nitrogen and a 37uC water bath. Lysates of uninfected
erythrocytes (uRBC lysate) were prepared in the same way.
HO-1 inducibility in neutrophils
Neutrophils were isolated from whole blood using CD15 beads
(Miltenyi, Germany). The purity of neutrophils was assessed by
flow cytometry and found to be 95.4% (95%CI: 93.6% to 97.1%).
Neutrophils were cultured for various times either with intact,
uninfected red blood cells (intact uRBC, containing 6.6 mM
heme), uRBC lysate or PfSE (containing 95.3 mM and 99 mMo f
heme, respectively), growth medium (GM), or 100 mM hemin
(Sigma Aldrich). Cell supernatants were harvested and assayed for
HO-1 by ELISA, and cells were collected into RLT buffer and
processed for HMOX1 mRNA as described under qRT PCR.
Neutrophil oxidative burst
To investigate the impact of hemin-induced HO-1 on the
neutrophil respiratory burst, 500 uL whole blood of 4 healthy
adult donors was diluted 1:1 in RPMI (Gibco) and incubated for
18 hours at 37uC, in 5% humidified CO2 atmosphere, with
different concentrations of hemin (0 to 200 mM). Half of the cells
were used to measure hemin-induced induction of HO-1 mRNA.
A small aliquot of cells was stained with a neutrophil marker (anti
CD15ab labeled with APC, Miltenyi) and the ‘live dead cell stain’
(Invitrogen) to assess the viability of neutrophils by flow cytometry
after pre-incubation with hemin. The oxidative burst was
measured using a validated flow cytometric assay on the
remainder of the cells [41]. Briefly, samples were stimulated by
adding PMA (Sigma) to a final concentration ranging from 0 to
1000 nM for another 15 minutes. Thereafter, dihydrorhodamine
123 (DHR 123) (final concentration 5 ug/ml) was added for
5 min. Red cells were lysed (with ammonium chloride lysis buffer)
and the remaining cells were stained with anti CD15 APC
(Miltenyi) and the median fluorescence intensity of rhodamine, the
fluorescent oxidation product of DHR 123, was measured in
CD15
+ cells by flow cytometry.
In a separate series of experiments 500 ml of whole blood from
another 4 healthy adult donors was incubated with 0–200 mM
hemin, either with or without addition of tin protoporhyrin IX
dichloride (SnPP; final concentration 10 mM), a non-substrate
inhibitor of HO-1 activity [42]. A viability check was performed as
described above, and the oxidative burst was induced by
stimulation with PMA at a final concentration of 100 nM for
15 min, and the burst was measured as described above.
Statistical analysis
Flow cytometric results, HMOX1 mRNA and HO-1 plasma
levels obtained on D0 and D28 were compared using linear
HO-1 Associated with Severe Malaria
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repeated measurements over time. Significance (measured at the
5% level) tests for the effects of malaria group (SM, UM), time (D0
and D28) and their interaction were adjusted for the possible
confounding effects of age, gender, duration of prior symptoms
and Hb levels, as indicated. Further adjustment for neutrophils
was performed for the analysis of WBC, and HO-1 mRNA.
Where there was no significant malaria group and time
interaction, p-values for the overall comparison of D0 vs D28
are given. Comparisons of SM vs UM are given for each time
point separately if the malaria group and time interactions were
significant. To allow for the multiple tests resulting from multiple
responses and multiple comparisons within a response performed
in the model, a false discovery rate (FDR) of 5% was assumed.
Using the Benjamini and Hochberg approach [43] only tests with
a p-value below 0.012 have an FDR of #5%.
Comparison of HMOX1 mRNA and HO-1 plasma levels
between different disease entities during acute disease was
performed using linear regression based on ranks, adjusting for
the confounding effects of age, gender, duration of symptoms, and
for neutrophil counts and Hb levels where indicated.
A multinomial logistic regression model was employed to
explore the association between the exposure ‘L allele containing
genotype’ and the outcome of different disease entities. Pearson
Chi-squared tests were used to compare proportions amongst
more than 2 groups. The magnitude of the differences of the long
L allele frequencies reported for African, Asian and European
populations was explored with fixation (FST) indices, using FSTAT
[44].
For the analysis of in vitro induction of HMOX1 mRNA in
neutrophils, pairwise comparisons using Wilcoxon matched pairs
test were performed, with p values adjusted for multiple
comparisons using Holm’s step down procedure. Where more
than two groups were compared, non-parametric one way
ANOVA (Friedman test for paired samples, Kruskal Wallis test
for unpaired samples) was used with Dunn’s post test adjustment
for multiple comparisons.
Linear regression was performed to assess whether the
magnitude of the oxidative burst induced by a given concentration
of PMA increases with increasing concentrations of hemin used for
pre-incubation. Analyses were performed using Stata version 10,
and Graph Pad PRISM version 5.01.
Results
In total, 154 uncomplicated (UM), and 153 severe malaria (SM)
cases were recruited into this study. The proportions followed up at
day 28 were 85.7% for the UM group and 83% for the SM group.
Ten children (6.5%) in the SM group died, and an additional 15
(9.8%) were either lost to follow up after hospital discharge or
withdrew consent. Nine of the ten deaths occurred in children who
were classified as having severe respiratory distress (SRD), defined as
lactic acidosis, that has been recognized as the single most important
determinant of mortality in severe malaria [45]. Children suffering
simultaneouslyfromSRD plus cerebralmalaria (CM)had thehighest
mortality (29.4%), followed by cases with SRD (16.7%). This is
consistent with a large study from Kenya, demonstrating that
mortality decreases in the following order for different disease
entities: [SRD+CM+severe anaemia (SA)].[SRD+CM].[SRD].
[SRD+SA].[CM].[CM+SA].SA].[severe prostration (SP)]
[46]. Where appropriate, cases were grouped according to disease
entities and analyzed in the order of increasing severity (Table S1 in
Text S1).
Neutrophils are the main HO-1 expressing cell type in
peripheral blood
To identify which leucocyte subsets express HO-1 protein,
whole blood collected on days 0 and 28 from 16 SM and 21 UM
cases was stained for lineage markers and intracellular HO-1
(Figure 1A–D). In SM, both the proportion and the total number
of white blood cells (WBC) expressing HO-1 was 2.2 and 1.3 fold
higher during the acute phase compared to convalescence (both
with p,0.0001, both adjusted and unadjusted). For UM cases, a
smaller difference was observed between time-points that became
non-significant after adjustment for percentage (number) of
neutrophils. (%WBC UM: p=0.280 [unadjusted: p,0.0001];
WBC number UM: p=0.31 [unadjusted: p=0.01]).
Both the percentage and total number of WBC expressing HO-
1 were significantly higher in SM than UM cases on day 0 (%
WBC: p=0.004 [unadjusted: p=0.001]; total WBC count:
p=0.009 [unadjusted p=0.008]), while no differences were
observed on day 28. Almost all neutrophils stained positive for
HO-1, both on D0 (median: 93%, CI 95%: 90.5–96%) and D28
(median: 97%, CI95%: 97–99%), with no difference between SM
and UM. Similarly, a median of 98% (CI 95%: 86–99.8%) of
neutrophils from healthy controls (HC) stained positive for HO-1
(Figure 1E). Western blot of isolated neutrophils from 4 cases
confirmed the presence of HO-1 in purified cells (Figure 1F).
Monocytes, B cells, T cells and DCs also expressed HO-1, albeit at
lower levels, rarely exceeding 4% of the lymphocyte subset
(Figure 1E). In both SM and UM cases the proportions of
monocytes, T cells and DCs expressing HO-1 were slightly but
significantly higher on D0 compared to D28 (p=0.002 [unad-
justed: p,0.0001], ,0.0001 [unadjusted: p,0.0001], ,0.0001
[unadjusted: p,0.0001], respectively; Figure 1E). The total
number of HO-1 positive neutrophils, monocytes and DCs was
significantly higher on Day 0 compared to D28 for both SM and
UM cases (p,0.0001 [unadjusted: p,0.0001], p=0.005, [unad-
justed: p=0.001], p,0.0001[unadjusted: p,0.0001], respectively;
Figure S1).
Irrespective of disease status (SM, UM, HC) or time of
sampling, a median of 98% (CI95%: 97.3–98.6%) of HO-1
expressing cells were neutrophils, whereas the other cell subsets
accounted for less than 1% of HO-1 producing cells in peripheral
blood (Figure 1G).
HMOX1 mRNA expression in whole blood cells and
plasma levels of HO-1 are elevated during acute malaria
RNA was extracted from 128 SM and 134 UM cases at both D0
and D28 from blood collected into PAX tubes to assess HMOX1
mRNA levels by qRT-PCR. Considering that neutrophils were the
major source of HO-1 in peripheral blood and that their numbers
are slightly higher in acute malaria compared to convalescence
[31], the random effects model (from which the p values are
derived) additionally adjusted for neutrophil counts to rule out that
the observed difference merely reflects different numbers of HO-1
producing neutrophils. For both SM and UM cases a geometric
mean 4.3 and 3.7 fold higher HMOX1 mRNA/18s rRNA ratio
was found during acute disease compared to convalescence
(p,0.0001 [unadjusted: p,0.0001], for both SM and UM,
Figure 2A), while no significant difference was observed between
SM and UM on D0 or D28.
When HMOX1 mRNA expression of peripheral blood cells was
assessed for different disease entities during acute disease
(Figure 2B), linear regression with UM as a baseline group
adjusting for age, gender duration of symptoms and neutrophil
counts revealed a trend towards higher levels with increasing
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classified as having SRD plus CM (p=0.04) [unadjusted:
p=0.19]. In the UM, SP, SA, CM and SRD groups HMOX1
mRNA levels at D0 were elevated similarly (3.1 to 4.8 fold higher
[geometric means] than on D28, p=0.36, for comparison among
groups, Kruskal Wallis test), but a significantly higher, 10.1 fold
increase was measured for the SRD+CM group (p,0.05
compared to UM, Dunn’s post test, adjusting for multiple
comparisons).
Considering that previous studies report increased HO-1
protein in plasma of critically ill patients, [47], we measured
HO-1 levels in plasma on days 0 and 28 for 138 SM and 137 UM
cases. Similar low levels of HO-1 were observed during
convalescence for both SM and UM, but HO-1 concentrations
measured during acute disease (D0) were 5.7 fold (SM) and 3.3
fold (UM) higher than on D28 (p,0.0001 for both groups
[unadjusted: p,0.0001 for both groups], Figure 2C), with HO-1
levels in SM being significantly higher than in UM at D0
(p,0.0001) [unadjusted: p,0.0001], but not day 28. Using
uncomplicated cases as the baseline group, plasma concentrations
of HO-1 measured on day 0 were significantly associated with
disease severity in a linear regression model based on ranks
adjusting for age, gender, and duration of symptoms (p,0.0001
[unadjusted: p,0.0001]). In particular, patients with SA, SRD
and SRD plus CM had significantly higher HO-1 plasma
concentrations (SA: p=0.004 [unadjusted: p=0.001], SRD:
Figure 2. HMOX1 mRNA and HO-1 protein are upregulated in acute malaria, being highest in cases with SRD. HMOX1 mRNA levels
measured in whole blood are shown comparing A) severe (n=128) and uncomplicated (n=134) cases over time, and B) different disease entities on
day 0. HO-1 plasma concentrations are shown comparing C) severe (n=138) and uncomplicated (n=137) cases over time, and D) different disease
entities on day 0. P values shown in A) and C) are derived from the random effects regression model, adjusting for age, gender, duration of symptoms
and neutrophil counts. P values shown in B) and D) are from a linear regression model adjusting for age, gender, duration of symptoms, neutrophil
counts and Hb. S=severe, U=uncomplicated, D0=day 0, D28=day 28. SRD=severe respiratory distress, CM=cerebral malaria, SA=severe anaemia,
SP=severe prostration, UM=uncomplicated malaria. The red lines represent the medians.
doi:10.1371/journal.ppat.1002579.g002
Figure 1. Neutrophils are the main HO-1 expressing cell type in peripheral blood. Whole blood from 16 SM and 21 UM cases was stained
for A) intracellular HO-1 expression [plots 3 and 4 in the first row show the isotype control], and B) for lineage markers defining neutrophils (CD16b),T
cells (CD3), monocytes (CD14), and B cells (CD19). Dendritic cells were defined as lineage marker negative HLA-DR pos cells. C) HO-1 positive cells
were displayed according to expression of lineage markers. D) Neutrophils, T cells, monocytes, B cells and DCs were displayed according to HO-1
expression. The Y axis in all plots is the side scatter (SSC). E) Proportion of white blood cell subsets staining for HO-1. F) representative Western blot
showing HO-1 immunoreactive protein in purified granulocytes [G=granulocytes, kDa=molecular weight maker] G) Percentage of HO-1 pos cells
according to white blood cell subsets. S=severe; U=uncomplicated cases; HC=healthy controls; D0=day 0; D28=day 28. The median with 95% CI is
shown for 16 severe, 21 uncomplicated cases and 6 healthy controls.
doi:10.1371/journal.ppat.1002579.g001
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unadjusted: p,0.0001]). After additional adjustment for Hb
concentration the overall association between severity and HO-1
levels remained significant (p=0.004). However, while HO-1
remained significantly elevated in cases with SRD (p=0.003) and
SRD plus CM (p=0.007), the difference previously seen in the SA
group was lost (p=0.12; Figure 2D). While the origin of plasma
HO-1 remains unclear, the latter observation supports the
hypothesis that it is derived at least in part from damaged tissues
[47]. By definition, SA cases have lower Hb levels, and a higher
degree of hemolysis, which is associated with considerable damage
of endothelial cells due to release of iron and heme-containing
moieties from hemolysed RBC [48]. Adjusting for Hb may even
out the effect of hemolysis-driven damage of endothelial cells that
may lead to HO-1 release into plasma.
However, additional factors may be responsible for the high
HO-1 levels found in patients with SRD, where a significantly
higher increase of HO-1 plasma levels was observed between D0
and D28 in patients with SRD or SRD plus CM compared to
other entities (p,0.0001, Kruskal Wallis test). While patients with
SP, SA or CM had 4.8, 7.7 and 5.5 fold higher values on D0
compared to D28, a 10.2 and 8.9 fold difference between D0 and
D28 was measured for patients with SRD plus CM or SRD,
respectively. This was significantly higher than the 3.3 fold
increase observed for UM (p,0.05, Dunn’s post test).
In summary, the data indicate that HO-1 production is induced
during acute malaria in peripheral blood cells and probably in
various other tissues, and the effect is greatest in cases with SRD.
Interestingly, for both SM and UM, HO-1 levels in plasma
correlated well with indirect bilirubin, one of the end products of
the reaction catalysed by HO-1, that is usually seen as an indirect
measure of HO-1 activity, and has been established as a marker
for disease severity [49] (r: 0.69, p,0.0001 [SM] and r: 0.77,
p=0.0012 [UM]; Figure S2).
Lysates of infected and uninfected RBCs can induce
HMOX1 expression in neutrophils in vitro
Considering that parasitaemia [%] correlated with HO-1 in
plasma (r: 0.5, p,0.0001) and the observation that the majority of
neutrophils contained HO-1, we investigated whether encounter
with P. falciparum antigens can induce HMOX1 expression in
neutrophils. To this end, HMOX1 mRNA expression was
determined by qRT-PCR in neutrophils purified from whole
blood of 7 donors using magnetic beads and cultured for 3 hours
with either growth medium (GM) (negative control), 100 mM
hemin (positive control), intact uninfected red blood cells (uRBC)
at 1610
8/ml, or freeze – thaw lysates of either uRBC or P.
falciparum Schizont extract (PfSE) at a concentration equivalent to
1610
8 cells/ml. Heme concentrations were measured in all RBC
preparations and were found to be 6.6 mM (intact uRBC),
95.3 mM (uRBC lysate) or 99 mM (PfSE). Culture with lysates of
both uRBCs and PfSE resulted in a significant increase in median
HMOX1 mRNA expression compared to culture in GM (2.3 and
2.7 fold with uRBC (p=0.04) and PfSE (p=0.01) lysate,
respectively), while HMOX1 mRNA remained at baseline levels
in neutrophils cultured with intact uRBCs (Figure 3). Culture in
the presence of hemin led to a significant, 4.4 fold median increase
in HMOX1 mRNA in neutrophils (p=0.023; all results adjusted
for multiple comparisons).
To evaluate whether neutrophils could contribute to plasma
HO-1 levels by releasing HO-1, we cultured bead-purified
neutrophils from an additional 4 donors using the above described
conditions for 3, 6, 12, 24 and 36 hours, respectively, and tested
the supernatants for HO-1 protein by ELISA. RNA was isolated
from neutrophils for determination of HMOX1 mRNA by qRT-
PCR. Although HMOX1 mRNA expression increased up to 6 hrs
in response to uRBC, PfSE and hemin no significant amount of
HO-1 could be measured in the supernatants for any of the
conditions tested (data not shown).
Taken together, these data demonstrate that HMOX1 mRNA
can be induced in neutrophils in response to hemin as well as RBC
lysates containing significant amounts of heme, and suggest that
heme released during RBC lysis rather than parasite-derived
molecules contribute to this increase. Further, we demonstrate that
neutrophils do not release HO-1 in response to these stimuli within
36 hours, and thus are unlikely to contribute to plasma HO-1.
In order to explore a correlation between free heme and HO-1
in plasma from our clinical samples, we attempted to quantify non-
protein bound (free) heme. After filtration of the samples heme
concentrations were barely measurable (median 1.42 mM, CI95%:
1.37–1.48 mM), being 4.6 fold lower than that in washed
preparations of intact uninfected RBCs. We therefore excluded
these data from further analysis. However, both RBC counts and
Hb levels that may be regarded as surrogates for the degree of
hemolysis, and therefore free heme in acute malaria, showed a
negative correlation with plasma HO-1 (r=20.34, p,0.0001 in
both cases).
Hemin-induced HMOX1 mRNA expression primes the
oxidative burst of neutrophils
The observation that HMOX1 expression can be increased in
neutrophils in response to heme prompted us to investigate the
role of HO-1 for the neutrophil respiratory burst. The oxidative
burst in neutrophils is essential for the host’s ability to kill ingested
microorganisms and parasites [50], but intense oxidative stress has
also been associated with severe forms of malaria, triggering
unspecific tissue damage [10]. To assess the impact of hemin-
mediated induction of HO-1 on the neutrophil function, the
respiratory burst in response to PMA stimulation (0, 0.05, 0.1 and
1 mM) was measured using a validated flow cytometric whole
blood assay [41] after overnight incubation of blood from 4
healthy donors with several concentrations of hemin. As expected,
pre-incubation with hemin induced HMOX1 mRNA expression in
Figure 3. Hemin and lysed RBC can induce HMOX1 mRNA in
neutrophils. Induction of HMOX1 mRNA in bead-isolated neutrophils
is shown in response to 3 hours stimulation with growth medium (GM),
intact uninfected RBC, a lysate of uninfected RBC, P. falciparum Schizont
extract (PfSE), or hemin. Experiments were repeated independently 7
times. Wilcoxon matched pairs test was performed with p-values
adjusted for multiple comparisons using Holm step down procedure.
Box plots show medians and interquartile ranges.
doi:10.1371/journal.ppat.1002579.g003
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2
lin regression=0.9, p=0.0052,
Figure 4A), and did not significantly affect the viability of
neutrophils (Figure 4B). While hemin pre-incubation alone did
not induce the oxidative burst, stimulation with 0.05, (0.1) or [1.0]
mM PMA reliably induced an oxidative burst in 94.4%, 96.5% and
96.9% of neutrophils, respectively (p=0.052, paired measures
ANOVA). For each PMA concentration, pre-incubation with
different hemin concentrations did not affect the proportion of
neutrophils responding with an oxidative burst (Figure 4C).
However, the magnitude of the oxidative burst induced with
Figure 4. Hemin-induced HMOX1 induction primes the oxidative burst of neutrophils. In 8 independent experiments, whole blood from
different donors was incubated for 18 hours with increasing amounts of hemin in the presence or absence of 10 mM SnPP and the neutrophil
oxidative burst induced by PMA was quantified by flow cytometric assessment of oxidation of dihydrorhodamine 123 into the fluorescent rhodamine.
A) HMOX1 mRNA levels induced by various concentrations of hemin. B) Viability of neutrophils after 18 hrs pre-incubation with 0–200 mM hemin. C)
Proportion of neutrophils that mount an oxidative burst, defined as positive rhodamine fluorescence. D) Magnitude of the oxidative burst in
neutrophils in response to stimulation with 0–1 mM PMA after 18 hrs pre-incubation with 0–200 mM hemin. E) Magnitude of the oxidative burst in
neutrophils in response to 0.1 mM PMA after 18 hrs pre-incubation with 0–200 mM hemin with or without addition of 10 mM SnPP. The mean and SE
are shown. MFI: median fluorescence intensity.
doi:10.1371/journal.ppat.1002579.g004
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with increasing concentrations of hemin used during the pre-
incubation (r
2
lin regression 0.92 [0.05 mM PMA] and 0.84 [0.1 mM
PMA], with p=0.037 [0.05 mM PMA] and 0.04 [0.1 mM PMA],
Figure 4D). When 1 mM PMA was used, the burst could be
maximally stimulated without preincubation with heme. This
suggests that hemin-mediated induction of HO-1 may prime
neutrophils to mount a stronger oxidative burst.
To further investigate whether the observed effect is mediated
by hemin-induced HO-1, we repeated the experiment in the
presence and absence of 10 mM tin protoporphyrin (SnPP), an
inhibitor of HO-1 activity, using whole blood from another 4
healthy volunteers in separate experiments. At this concentration,
SnPP did not significantly affect neutrophil viability compared to
pre-incubation with hemin alone (p=0.125 [0 mM hemin], 1.0
[0.05 mM hemin], 0.125 [0.1 mM hemin] and 0.625 [1 mM
hemin], Wilcoxon signed rank test). Further, the addition of
10 mM SnPP did not affect the proportion of neutrophils
responding with an oxidative burst to stimulation with 0.1 mM
PMA, compared to pre-incubation with hemin alone (p=0.375
[0 mM hemin], 0.25 [0.05 mM hemin], 0.875 [0.1 mM hemin]
and 0.625 [1 mM hemin], Wilcoxon signed rank test). However,
hemin pre-incubation in the presence of 10 mM SnPP abrogated
the hemin dose-dependent increase of the oxidative burst
(r
2
lin regression 0.88, p=0.035 [no inhibitor] and r
2=0.22,
p=0.23 [with inhibitor], Figure 4E). Taken together, the data
indicate that heme-mediated induction of HO-1 primes the
oxidative burst in neutrophils.
Other factors that may induce HO-1
Apart from the availability of its substrate heme, other factors
may induce HO-1. In animal models [51], and human hepatoma
cell lines [52] HO-1 could be induced by heat exposure. However,
in human alveolar macrophages or erythroblastic cell lines [53], as
well as in PBMC [54] thermal stress failed to induce HO-1. Since
we observed a weak but significant positive correlation between
temperature on admission to the clinic and HO-1 plasma levels
(r: 0.266, p,0.0001), we explored whether a temperature of 40uC
maintained over 3 hours would induce HMOX1 mRNA in human
whole blood, using samples collected on D28 from 12 SM, 20 UM
cases and 6 HC. Samples kept at 37uC or cultured with hemin
served as negative and positive controls, respectively.
In all three groups (SM, UM, HC) both incubation at 40u as
well as with hemin resulted in a significant upregulation of
HMOX1 mRNA compared to cells kept at 37uC, with no
significant differences observed between groups (Figure 5A). In a
separate experiment using blood from 5 healthy donors we verified
that incubation at 40uC for 3 hours did not lead to a significant
change in hemolysis markers such as heme, haptoglobin or LDH,
compared to incubation at 37uC (data not shown).
For murine macrophages, IL-10 has been shown to induce HO-
1 [55]. We therefore correlated HMOX1 mRNA to IL-10 mRNA
from D0 samples for 58 SM and 59 UM cases for which IL-10
mRNA measurements were available from a previously reported
study [31]. For both SM and UM a positive correlation (SM: r
=0.59, p,0.0001; UM: r=0.37, p=0.0037) was found in whole
blood, compatible with a role for IL-10 as an inducer of HO-1 in
human blood cells (Figure 5B, C).
HMOX1 promoter genotypes without L-allele are
associated with SRD and mortality
The extent to which HMOX1 is upregulated in an individual in
response to a defined stimulus may be influenced by genetic
polymorphisms in the promoter region of the HMOX1 gene of
which several have been described, (reviewed by [16]). Of
particular interest, a (GT)n repeat length polymorphism regulates
the promoter activity and gene expression, with short repeats (,27
repeats) resulting in an increased transcription of HMOX-1
compared to alleles with long repeats (.32 repeats) [33,56].
Associations of the (GT)n polymorphism with disease outcomes
have been explored in numerous association studies for various
Figure 5. Other factors associated with HMOX1 mRNA expres-
sion. A) HMOX1 mRNA was measured in whole blood from
convalescent SM (n=12) and UM (n=14) cases and healthy controls
(HC, n=6). For 3 hours, blood was kept in a water bath at 37uC, 40uCo r
stimulated at room temperature with hemin. Measurements within
each group (SM, UM, HC) were compared using the Friedman test, (a
non-parametric ANOVA for repeated measures) with Dunn’s post-test
adjustment for multiple comparisons. Differences between SM and UM
for hemin or heat induction were assessed using the Mann Whitney
test. The red lines indicate the medians. * p#0.05, ** p#0.005,
*** p#0.0005. mRNA levels for HMOX1 and IL-10 measured on day 0
were correlated for B) 58 SM [r: 0.59, p,0.0001] and C) 59 UM cases [r:
0.37, p=0.0037].
doi:10.1371/journal.ppat.1002579.g005
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(GT)n polymorphism is associated with disease severity in malaria,
we genotyped this microsatellite for 142 SM and 151 UM cases for
whom DNA samples were available.
In the study population (GT)n variation ranged from 13 to 45
repeats, and the allele frequency distribution was trimodal with
peaks at 26, 30 and 39 repeats (Figure 6A). Using a previously
established classification [33,34,36], alleles were divided into 3
groups: ‘‘S’’ (,27 repeats), ‘‘M’’ (27 to 32 repeats), and ‘‘L’’ (.32
repeats). The frequency of ‘‘S’’ alleles was significantly higher in
SM cases (0.50 vs. 0.37, p=0.0021), whereas the frequency of ‘‘L’’
alleles was significantly higher in UM cases (0.36 vs 0.26,
p=0.009, Figure 6B). The frequency of different alleles according
to disease entities is shown in Figure 6C.
Based on the ‘‘S-M-L’’ classification, six genotypes (SS, SM,
MM, ML, LL and SL) were defined. As shown in Figure 6D, the
Figure 6. Long (GT)n repeats and ‘‘L carrier’’ genotype associate with less severe disease. A) Frequency distribution of the number of
[GT]n repeats in SM (open bars, n=282 alleles) and UM cases (black bars, n=302 alleles). B) Frequency of the ‘‘S’’ (short,27), ‘‘M’’ (medium 27 to 32)
and L (long.32) [GT]n repeats for SM (open bars) and UM (black bars) cases. C) Frequency of ‘‘S’’ (open bars), ‘‘M’’ (dotted bars) and ‘‘L’’ (black bars)
[GT]n repeats according to disease entities. Distribution of HMOX1 promoter genotypes amongst D) SM (open bars) and UM (black bars) cases, and E)
amongst different disease entities. Those labeled in green are ‘‘L carriers’’, those labeled in red are ‘‘non-L carriers’’. SM=severe malaria, SRD=severe
respiratory distress, CM=cerebral malaria, SA=severe anaemia, SP=severe prostration, UM=uncomplicated malaria.
doi:10.1371/journal.ppat.1002579.g006
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compared to UM cases (27.5% vs. 8%, p,0.00001). Conversely,
the ‘‘SL’’ genotype is more prevalent in UM cases (35% vs. 21.8%,
p=0.012). Figure 6E depicts the frequency of the 6 genotypes for
each disease entity. When dichotomized as described previously
[34,56] into genotypes containing at least one ‘‘L’’ allele (LL, ML,
SL=L-carriers; labeled green in Figure 6E) versus non-L carriers
(SS, SM, MM; labeled red in Figure 6E), SM patients were 53%
less likely to be L carriers than UM cases (OR: 0.47, CI 95%: 0.29
to 0.75, p=0.002). When L carrier status was analysed in relation
to different disease entities using multinomial logistic regression,
cases with SRD and SRD plus CM were significantly less likely to
be L carriers (85% and 74% less likely, respectively) compared to
uncomplicated cases (Table 1). Of note, 9 out of the 10 individuals
who succumbed to malaria were non-L carriers, compared to
53.4% non-L carriers within the remaining severe cases (p=0.043,
Fisher’s exact test), or 37% non-L carriers within UM cases
(p=0.003, Fisher’s exact test).
We further examined whether ethnicity was associated with
either disease outcome, frequency of L alleles or L allele
containing genotypes. We found that ethnicity was not associated
with being a SM or UM case (p=0.294), or with any of the
particular disease entities (p=0.112). There was also no difference
in the frequency of the L allele (p=0.063) or of the L allele-
containing genotypes (p=0.088) among ethnic groups.
The effect of HMOX1 genotype on disease severity is not
influenced by other factors associated with disease
severity
To determine a possible confounding effect of some of the major
factors known to determine disease severity, we measured the
frequency of sickle cell trait, blood group O and G6PD deficiency,
and the level of HRP-2 in our study population.
Hemoglobin S (HbS) confers protection from severe malaria in
humans [57], and was recently shown to induce HO-1 in murine
hematopoietic cells [58]. Blood group O has been associated
repeatedly with reduced risk of severe malaria [59], and so has
been G6PD deficiency [60,61], as hypothesized by Allison [62]. In
agreement with two previous studies using samples from this
geographic area [37,63], we confirmed the 968C/376G allele as
the most common G6PD A- deficiency allele in our study
population (6.26%). The latter study from the Gambia [37]
suggested that heterozygous females and hemizygous males are
relatively protected from severe disease. The histidine-rich-protein
2 (HRP-2) has been proposed as a surrogate for parasite biomass
and is considered to be associated with disease severity [64]. Figure
S3 shows the frequency of these factors according to disease group
and HMOX1 genotype. In our study population, carriage of the
sickle cell trait, G6PDA
2, or blood group O were neither
associated with disease severity, nor with HMOX1 genotype. As
expected, HRP-2 was associated with disease severity, but showed
no association with HMOX1 genotypes.
Higher HMOX1 mRNA induction in non-L allele carriers
To examine whether the genotype of the (GT)n polymorphism
was associated with the magnitude of HMOX1 mRNA induction
in peripheral blood leucocytes in response to a defined stimulus,
the data for hemin and heat-mediated induction of HMOX1
mRNA in whole blood collected on D28 shown in Figure 3B were
plotted according to L carrier status (Figure 7).
Both L and non L carriers had similar HMOX1 expression at
baseline (p=0.65), and showed a significant 2.5 fold (L carriers,
p=0.0002), or 4.3 fold (non L carriers, p=0.002) increase in
HMOX1 mRNA levels in response to heat. When hemin induced
HMOX1 mRNA levels were compared to baseline a 4.7 fold (L
carriers, p=0.0002), or 17.1 fold (non L carriers, p=0.0039)
increase was observed. Importantly, the median HMOX1 mRNA
measured in non-L carriers after hemin stimulation was 3.9 fold
higher (p=0.0028) than was observed in L carriers (Figure 7). In
response to heat stimulation, non L carriers had 1.9 fold higher
mRNA levels compared to L carriers (p=0.183). After Bonferro-
ni’s adjustment for multiple comparisons the significance threshold
for these tests becomes 0.007. The differential HMOX1 mRNA
Table 1. Association between L allele containing genotype and different disease entities.
SM (all
entities)
OR (95% CI)
p
value
SP
RR (95% CI)
p
value
SA
RR (95% CI)
p
value
CM
RR (95% CI)
p
value
SRD
RR (95% CI)
p
value
SRD+CM RR
(95% CI) p value
L carrier 0.47 (0.29–0.75) 0.002 0.62 (0.36–1.07) 0.087 0.71 (0.21–2.42) 0.582 0.47 (0.18–1.26) 0.135 0.15 (0.05–0.46) 0.001 0.26 (0.08–0.89) 0.032
0.49 (0.31–0.8) 0.004 0.66 (0.38–1.16) 0.148 0.61 (0.17–2.18) 0.446 0.48 (0.18–1.32) 0.155 0.16 (0.05–0.52) 0.002 0.28 (0.08–0.95) 0.042
(SM=severe malaria, all entities, SP=severe prostration, SA=severe anaemia, CM=cerebral malaria, SRD=severe respiratory distress). In the top row, the odds ratio
(OR) is shown for the association between L allele carriage and SM/UM, and a risk ratio (RR) is shown for the association between L allele carriage and each of the disease
entities versus UM. (CI 95% refers to 95% confidence intervals of the estimates). The second row in italics shows similar results for the corresponding analyses adjusted
for ethnicity.
doi:10.1371/journal.ppat.1002579.t001
Figure 7. Higher HMOX1 mRNA induction in peripheral blood
from ‘‘non-L allele’’ carriers in response to hemin. Induction of
HMOX1 mRNA after 3 hrs exposure to 40uC or 100 mM hemin is shown
according to L/non L carrier status for 26 individuals, using blood
collected on D28. The red line represents the median. Raw p values are
reported. After Bonferroni’s adjustment for multiple comparisons the
significance threshold becomes 0.007.
doi:10.1371/journal.ppat.1002579.g007
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with what has been reported from human lymphoblastoid cell lines
treated with H2O2 [33], and demonstrates that in our study
population the magnitude of HMOX1 mRNA expression in
peripheral blood leucocytes in response to a defined stimulus is
associated with the length of the (GT)n repeat.
Linkage disequilibrium around the HMOX1 locus and
population frequencies of L - alleles
To investigate the possibility that, in West Africans, the (GT)n
microsatellite is tightly linked to (or ‘‘tagging’’) unexplored
functional variants in alternative genes, we analyzed the extent
of linkage disequilibrium (LD) at and around the HMOX1 locus,
using HapMap data for Nigerian Yoruba. In this West African
population, the (GT)n microsatellite in the promoter lies in a 6KB
LD block that extends from rs2071746 (59) to rs11912889 (39),
encompassing approximately half of the HMOX1 gene. According
to these data, the (GT)n microsatellite would effectively tag only
variants within HMOX1, but no other genes. Moreover, the two
genes immediately flanking the HMOX1 gene (TOM1 33 kb 59 and
MCM5 6k b3 9 of HMOX1) are not obvious candidates for malaria
susceptibility (Figure S4). Future comparative studies of LD would
be ideally conducted in the Gambian ethnic groups, and will
benefit from whole genome sequence data likely to emerge from
initiatives including the 1000 Genomes Project [65].
The frequency of the long (.32 copy) repeat alleles was similar
to that recently reported from Angola [30], but significantly higher
than was reported from populations living in areas where malaria
is not endemic, such as Europe (French [66], German [67]), and
North America (Caucasians, [68]) or Asia (Japanese [34,36,69],
Karen people from Myanmar [29]; see Table S2 in Text S1). The
magnitude of the differences was therefore explored with fixation
(FST) indices. Differences between the Gambian and North
American (FST=0.29), or European populations (Gambia vs
France, FST=0.21; vs Germany, FST=0.14) were slightly higher
than the average for a genome-wide sample of polymorphisms
(FST=0.126, [70]), whereas differences between Gambian and
Asian populations (FST for Gambia vs Myanmar, or vs Japan) were
slightly less than the genome-wide average. In the Angolan
population allele frequency of the long repeat alleles was higher
than in The Gambia, and therefore slightly more divergent from
the non-African population samples (Table S3 in Text S1). When
available data from each continent were pooled, the largest FST
values were observed for comparisons between Africa and
America (FST=0.33 CI 95%: 0.29 to 0.38), Africa and Europe
(FST=0.25 CI 95%: 0.2 to .29), and Africa and Asia (FST=0.21
CI 95%: 0.18 to 0.25; Table S4 in Text S1).
Discussion
Inspired by elegant studies in murine malaria models clearly
demonstrating that the induction of HO-1 helps prevent severe
forms of malaria [9,10], and the intriguing possibility either to
manipulate HO-1 activity pharmaceutically [71,72] or to mimic its
effect by administering CO [20], we explored the role of HO-1 in
children with severe and uncomplicated P. falciparum infection.
During acute disease, the number of WBC staining positive for
HO-1, the HMOX1 mRNA levels, and the HO-1 protein
concentrations in plasma were significantly higher than during
convalescence, being highest in the most seriously ill patients
presenting with SRD.
While the association between elevated HO-1 and severe illness
we and others [47,68,73] observed might merely reflect an
appropriate response insufficient in magnitude and/or occurring
too late, the association between short (GT)n repeat alleles and
increased inducibility of HO-1 in vitro, and more severe disease
suggests that HO-1 levels above a certain threshold may be part of
the causal pathway leading to severe disease and death. The
association between short (GT)n repeat alleles in the HMOX1 gene
promoter region (resulting in enhanced HMOX1 mRNA expres-
sion) with CM observed in a small study in Myanmar [29], and
more recently, in Angola [30] supports this notion. Intriguingly,
both our study and the study carried out in Angola [30] observed a
distinct peak around 39 (GT)n-repeats, which is in contrast to
previous data from populations from non-malaria endemic areas
[34,36,66,67,68,69]. We have noted that the FST indices for
comparisons between these two African populations and those
from non-malaria endemic areas were slightly above the average
for a genome-wide sample of polymorphisms [70], although more
detailed study of polymorphism in this gene would be needed to
test a neutral hypothesis. The possibility that the relatively high
frequency of long (GT)n repeats in Africa may have resulted from a
survival advantage from P. falciparum should encourage investiga-
tion to prospect more powerfully for evidence of selection on this
locus, given that malaria has been one of the most powerful
selective forces acting on the human genome [74].
The fact that increased levels of indirect bilirubin and COHb –
both end products of the reaction catalyzed by HO-1 – are widely
recognized as independent markers for mortality in critically ill
patients [23,49], and that long (GT)n alleles were associated with
less frequent multi organ dysfunction in European ICU patients
irrespective of the specific diagnosis [47], make it tempting to
speculate that a high HO-1 response is disadvantageous for acute
inflammatory conditions in general. In fact, HO-1-induced CO
may reduce oxygen carrying capacity in the blood and tissue
oxygenation, ultimately leading to metabolic acidosis. Further-
more, increased HO-1 may result in low nitric oxide (NO) levels
[75]. This may constitute another pathway by which over-
expression of HO-1 contributes to severe disease based on the
beneficial effects ascribed to inhaled NO on endothelial function in
patients with adult respiratory distress syndrome (ARDS) [76], and
the accumulating evidence that depletion of NO contributes to
severe malaria [77]. Considering that HO-1 overexpression in the
liver leads to an increase in parasite liver load [11], and that the
major benefit of RTS,S (a malaria vaccine that partially reduces
the parasite burden in the liver) is the reduction of severe disease, it
is tempting to speculate that particularly high HO-1 levels in the
liver might contribute to severe malaria in man.
These findings differ from the role HO-1 plays in preventing
severe disease in mice [8,10]. An attempt to reconcile these
observations needs to take into account that mice in contrast to
humans lack the (GT)n repeat polymorphism [18]. The functional
relevance of the human (GT)n promoter length polymorphism
indicated here and elsewhere [33,56] suggests that humans might
have a greater genetically determined variability of HMOX1
expression than exists among inbred mouse strains. The infection
of BALB/c mice with P. berghei ANKA, for example, results in a
fairly homogeneous 3–4 fold upregulation of HMOX1 mRNA 6
days post infection [9], comparable to what we observed in
uncomplicated cases. However, a more than 10 fold difference was
measured in the most seriously ill patients of the SRD plus CM
group. In fact, HO-1 has both pro-and anti-oxidant properties
[24], and dependent on its amount, diametrically opposed effects
have been described: Several in vitro studies have shown that
moderate (less than 5 fold) induction of HO-1 is associated with
protection against heme-mediated damage [78], while higher
levels (greater than 10 fold) resulted in loss of cytoprotection [79].
Using HO-1 transfected hamster fibroblasts with either low,
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HO-1 related cytoprotection turns into HO-1 mediated oxidative
injury with increasing HO-1 expression [27]. Importantly, ferrous
iron accumulated in high HO-1 expressing cells, and the addition
of iron chelators or specific HO-1 inhibitors significantly reduced
all measures of oxidative tissue injury [27]. The notion that high
levels of HO-1 activity may potentiate, rather than attenuate ROS
toxicity, and that this is related to the increased availability of
ferrous iron is further supported by several in vitro studies [80,81],
as well as studies in animals [82,83].
Thus, we hypothesize that, up to a certain level, induction of
HO-1 is protective, while excessive upregulation of HO-1 in
response to an inflammatory stimulus is deleterious.
The clinical relevance of free iron in severe malaria infections
has been investigated previously, and high transferrin saturation
(which indicates mobilization of ferrous iron) was associated with
delayed recovery from coma in CM patients [84]. While HO-1
was not measured in this trial, a more recent study in patients with
ARDS established that transferrin saturation increased in parallel
to HO-1 [85], strengthening the idea that in vivo high HO-1 levels
may result in a clinically relevant increase of ferrous iron.
However, results of studies on the usefulness of iron chelation
therapy with desferroxiamine in malaria patients have been
inconclusive [86,87].
We also provide mechanistic evidence that hemin-mediated
HMOX1 mRNA expression in neutrophils potentiates the
magnitude of the neutrophil oxidative burst, and propose that a
genetic predisposition to high levels of HO-1 may cause an
otherwise protective response to become deleterious. By demon-
strating how the neutrophil oxidative burst may influence disease
severity, our data help to determine the role of this cell subset in
the pathogenesis of severe malaria, which is currently ill-defined.
Earlier in vitro studies established that iRBCs can be phagocytosed
by neutrophils [88], and can activate them to produce ROS [89],
which can kill parasites [50,90]. In line with this, the amount of
ROS produced by neutrophils from children with P. falciparum
infection was associated with faster parasite clearance [91], and
clinical protection from P falciparum correlated with neutrophil
respiratory burst induced by merozoite antigens opsonized by
antibodies [92], proposing neutrophils as an efficient defense
mechanism. However, in murine models of severe malaria, early
depletion of neutrophils prevents experimental CM [93], as well as
sequestration of neutrophils to the lungs and reduces mortality
[94], demonstrating that neutrophil effector mechanisms are
capable of contributing to severe disease. Taken together, this
suggests that an early neutrophil oxidative burst may benefit the
host by contributing to initial parasite control, while a genetic
predisposition towards an enhanced oxidative burst as suggested
by our data may result in enhanced damage of endothelial cells,
especially in conditions where neutrophils become sequestered in
capillaries.
Consistent with our data, a genome-wide analysis of the host
response to malaria recognized neutrophil-related gene expression
responses as the principal pattern distinguishing convalescent from
acute malaria patients, and the HMOX1 gene was amongst the
genes showing a stepwise increase with increasing severity [14].
The nature of the association between HO-1 in plasma and
severe disease, and whether or not soluble HO-1 has a causal role
in the pathogenesis of severe disease isn’t entirely clear, but we
consider it unlikely that HO-1 is functional in plasma. HO-1 is an
intracellular enzyme [95,96], and a molecule transporting HO-1
into the extracellular compartment has not been described.
Furthermore, enzymatic functionality of HO-1 requires its C
terminal end to be located in the membrane of the endoplasmic
reticulum (ER) [97], and several electrons to be provided by an
ER-bound NADPH cytochrome p-450 [98,99]. Like Saukkonen
et al. [47], we speculate that plasma HO-1 leaks from damaged
tissue, and the association between plasma HO-1 and severe
disease is primarily driven by the degree of tissue damage and not
the degree of HO-1 induction itself. It is therefore not surprising
that the HMOX1 genotypes show no clear association with plasma
HO-1 (Figure S5A). Based on the negative association we observed
between plasma HO-1 and RBCs or Hb (both can be seen as
markers of hemolysis in malaria), and considering that the release
of free iron and heme-containing moieties that occurs during
hemolysis leads to considerable damage of endothelial cells
[48,100,101], we propose damaged endothelial cells as an
important source of plasma HO-1.
This study had several limitations. In order to study HO-1
protein levels in WBCs according to disease entities or (GT)n
repeat polymorphisms, flow cytometric examination of blood from
more participants would have been required.
In view of the results we obtained for the comparison of in vitro
stimulated whole blood showing a significant difference in
HMOX1 mRNA expression between L and non L carriers in
response to a defined amount of hemin (Figure 7), the lack of an
association between HMOX1 genotype and HMOX1 mRNA
expression ex vivo (Figure S5B) or the lack of a clear difference in
HMOX1 mRNA levels between SM and UM cases may be
surprising. However, it is important to note that in contrast to the
in vitro experiment where the nature and the strength of the
stimulus is known, in vivo HMOX1 mRNA expression may be
driven by a variety of stimuli. To explore this further, it would
have been necessary to measure various factors known to induce
HMOX1 mRNA expression in vivo. In this regard, our inability to
measure free heme in plasma, known to be a major stimulus for
HO-1, was an unforeseen limitation. We can therefore only
speculate that inter-individual differences in the nature and
amount of HMOX1 mRNA inducing factors may have obscured
the effect of the HMOX1 promoter polymorphism on HO-1 levels
in vivo.
With this caveat in mind, our data do indicate that a genetic
factor affecting high HO-1 levels in response to heme is associated
with more severe disease and death from malaria. We identified
neutrophils as the predominant source of HO-1 in peripheral
blood, provide evidence that increasing HMOX1 mRNA
expression in these cells enhances the oxidative burst, and suggest
that this may constitute a mechanism by which sequestered
neutrophils cause tissue damage, thereby contributing to severe
pathology. Considering that similar associations between high
HO-1 and illness severity have been observed in other conditions
[47,73], limiting HO-1 activity pharmacologically with tin
protoporphyrin IX [71] or other inhibitors may be an interesting
therapeutic option worth considering.
An alternative therapeutic strategy might alter the distribution
of HO-1 induction to particular cell types by therapeutic
administration of haptoglobin or hemopexin, which both might
limit the toxicity of free heme and restrict the uptake of cell free-
hemoglobin and heme, and consequently upregulation of HO-1,
to those cells bearing receptors for these molecules.
Supporting Information
Figure S1 Total numbers of HO-1 expressing leucocyte
subsets. The total numbers of cells that stained positive for HO-1
are shown for A) all white blood cells, B) neutrophils, C)
monocytes, D) B cells, E) T cells and F) dendritic cells in blood
from 14 severe (S) and 21 uncomplicated (U) cases. P values are
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age, gender, duration of symptoms and Hb. The red lines show the
medians.
(TIF)
Figure S2 Correlation between HO-1 and indirect
bilirubin in plasma is shown for A) severe (n=46, r:
0.69 p,0.0001) and B) uncomplicated malaria (n=14, r:
0.77, p=0.0012) cases.
(TIF)
Figure S3 Possible confounding factors. The percentage of
A) sickle cell trait carriers and B) children who are heterozygous
(girls)or hemizygous (boys) carriers for the GdA
2 variant of G 6PD
deficiency are shown amongst severe (SM) or uncomplicated (UM)
malaria cases, or amongst those classified as ‘L’ or ‘non-L carriers’
for the (GT)n repeats. C) The percentage of children with blood
group O is shown according to disease entity (left), or HMOX1
promoter genotype (right). Error bars indicate the 95% CI for
proportions, calculated using the Wilson method. P values are
given for Fisher’s exact test (A), or Chi Square test (B and C),
respectively. D) Histidin rich protein-2 levels are shown according
to disease entity (left), or HMOX1 promoter genotype (right). The
red line indicates the geometric mean. The p-value refers to
regression analyses performed on log transformed data. (SP=se-
vere prostration, SA=severe anaemia, CM=cerebral malaria,
SRD=severe respiratory distress, UM=uncomplicated malaria).
(TIF)
Figure S4 HapMap LD structure of the HMOX1 locus.
The (GT)n promoter polymorphism is located 138 bp upstream
from rs2071746, at the left end of the 6 kb block. LD blocks are in
the HaploView format, with both D’ and r2 values shown.
(TIF)
Figure S5 HO-1 plasma levels and HMOX1 mRNA levels
according to HMOX1 promoter genotype. A) HO-1 plasma
levels and B) HMOX1 mRNA levels are shown for HMOX1
promoter genotypes, constituted of ‘‘S’’ (short,27), ‘‘M’’ (medium
27 to 32) and L (long.32) [GT]n repeats alleles. The red line
indicates the median.
(TIF)
Text S1 Table S1 provides additional information on
study participants according to clinical entities. * IQR:
Inter Quartile Range; ** weight-for-age z-scores for children up to
the age of 10 years (10 years inclusive); WHO Growth Standards:
For calculation of the z-scores the WHO packages ‘‘igrowup_
stata’’ and ‘‘who2007_stata’’ for up to 5 years old and .6t o1 0
year old children, respectively, were used. (http://www.who.int/
childgrowth/software/en/ and http://www.who.int/growthref/
tools/en/). (SP=severe prostration, SA=severe anaemia, CM=
cerebral malaria, SRD=severe respiratory distress, UM=uncom-
plicated malaria). Table S2 shows an inter-population comparison
for the HO-1 allele frequency analysis. The figures in bold print
are the pooled data for each continent. Table S3 presents pairwise
FST values for HO-1 length polymorphism allele frequency
divergence between populations (.32 repeat alleles vs shorter
alleles). The references of source data are in brackets. Table S4
presents pairwise FST values for HO-1 length polymorphism allele
frequency divergence between continents (pooled data derived
from table S2).
(DOC)
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